GlassScriptPhysician profile
Ghazi Asaad
NPI 1194767681
$29,462.38
in general payments reported to CMS, 2019-2025
37 companies · $4,460 in 2025
The $4,460 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,876 · 2020: $3,033 · 2021: $4,773 · 2022: $4,834 · 2023: $4,692 · 2024: $4,793 · 2025: $4,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,945.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,769.99 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $3,064.93 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $2,622.69 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $2,342.34 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $2,252.02 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,483.68 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,423.21 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,366.27 | 2019-2025 | Rexulti |
| Alkermes, INC. | $981.36 | 2019-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $884.79 | 2022-2025 | Auvelity, Sunosi |
| Corium, LLC | $874.55 | 2022-2025 | Azstarys |
| Allergan, INC. | $862.09 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $838.42 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $781.95 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $754.13 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $647.65 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $396.34 | 2019-2022 | |
| Bausch Health US, LLC | $308.51 | 2021-2024 | Aplenzin, Wellbutrin |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $306.32 | 2020-2025 | Rejoyn, Abilify Maintena, Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $296.28 | 2019-2023 | Jornay Pm |
| Eisai INC. | $289.88 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $289.44 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Merck Sharp & Dohme LLC | $288.53 | 2019-2023 | Belsomra |
| Adlon Therapeutics L.P. | $268.77 | 2019-2021 | |
| Tris Pharma INC | $225.82 | 2021-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $191.14 | 2022-2025 | Quviviq, Quviviq |
| Almatica Pharma LLC | $103.27 | 2021-2025 | Loreev Xr |
| Tempus Ai, INC | $99.78 | 2024 | |
| Shire North American Group INC | $95.83 | 2019 | |
| Neos Therapeutics, LP | $78.10 | 2023 | Adzenys Xr-Odt |
| Vertical Pharmaceuticals, LLC | $71.99 | 2024-2025 | Relexxii |
| E.R. Squibb & Sons, L.L.C. | $59.17 | 2024-2025 | Cobenfy |
| Arbor Pharmaceuticals, INC. | $51.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.37 | 2025 | |
| Sage Therapeutics, LLC | $22.93 | 2024 | |
| Harmony Biosciences LLC | $21.91 | 2020 | |
| Noven Therapeutics, LLC | $17.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghazi Asaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.